About Emobot
We built the tool we wished existed.
Psychiatrists see their patients once a month. Patients live their depression every day. Emobot exists to close that gap, with a patient-facing app that follows mood, speech, activity and sleep, and gently invites the patient to rebook with their clinician when things start to dip.
Our mission
Close the monitoring gap in psychiatry.
Without surveillance.
When a patient leaves a TMS or Esketamine session feeling better, that’s a win. But 50% of TRD patients relapse within a year, and 60% of those relapses are never caught, because there’s no monitoring in place.
Emobot is the Depression Thermometer: continuous, multimodal, passive, and entirely patient-facing. The patient owns the data. When the signals dip, they’re invited to rebook an appointment, and they come back in before they quietly drop off.
Founded in April 2022 at the Paris Brain Institute (ICM). 11 clinical studies. 4 patents. 7 academic partners across 4 countries. 150+ physicians. Post-early-PMF, pre-scale, and entirely focused on US interventional psychiatry.
Apr 2022
Founded · Paris, ICM
11
Clinical studies
4
Patents
7
Academic partners
150+
Physicians deployed
4
Countries
Founding team
Clinicians, engineers, and scientists, united by one problem.
Tanel Petelot
CEO & Co-founder
Commercial · Go-to-market
UC Berkeley and CentraleSupélec. Leads commercial strategy and GTM from day one. 10k+ followers in the psychiatry community on LinkedIn, ~4 qualified inbound leads per week.
Antony Perzo
CTO & Co-founder
AI · Multimodal fusion
CentraleSupélec. Leads the AI platform and on-device neural network design. First author of the EMOCARE pooled clinical validation poster (r = 0.895 MADRS rmCorr) presented at ASCP 2026 with NRx Pharmaceuticals and Johns Hopkins.
Samuel Lerman
CPO & Co-founder
Product · Patient experience
CentraleSupélec. Owns the patient and clinician product surfaces. Designs the passive-signal nudge loops behind 80% patient activation when a clinician proposes it and installs it in the visit.
Prof. Renaud Séguier, PhD
CSO & Co-founder
Science · Signal processing
Professor at CentraleSupélec, leads the AIMAC research team. Previously co-founded Dynamixyz (acquired by Take-Two, 2020). Scientific backbone of Emobot's multimodal approach and clinical validation design.
Core team
Martin Langlade
Chief Strategy Officer
Strategy · Partnerships
10+ years in digital health. Ex-Tilak Healthcare; led the $8M remote-monitoring reimbursement and $3M Novartis partnership. Runs strategy, partnerships, and regulatory.
Benoît Sauveton
Lead Developer
Tech · Clinician dashboard
+15 years in software engineering. Ex-Capgemini, Colibee, Gfi, Habiteo, Centurion, Castelis. Owns the clinician dashboard and the portal.emobothealth.com platform.
Timothée Schmidt
AI Engineer
AI · On-device inference
Mines Paris. Previously at Mistral AI. Owns the on-device inference stack and facial-affect models that keep Emobot raw-data-free.
Pyotr Shulzhenko
AI Engineer
AI · Multimodal modeling
École Polytechnique. Previously at IRA Labs, GE Healthcare, and Saint-Gobain. Works on multimodal fusion and vocal biomarker pipelines.
+ research, clinical and engineering contributors across Paris, the US and Canada.
Medical & scientific advisors
Psychiatrists and researchers who shape the clinical roadmap.
Dr. Carlene MacMillan, MD, FCTMSS
Co-founder & CPO, Radial Health · ex-CMO Osmind
Harvard-trained interventional psychiatrist. Co-founded Radial Health (national IP clinic network, $50M Series A led by General Catalyst, 2025). Previously CMO at Osmind.
Dr. Owen Scott Muir, MD, DFAACAP
Co-founder & CMO, Radial Health · Interventional psychiatrist
Board-certified adult, child & adolescent psychiatrist. Co-founded Radial Health with Carlene MacMillan. Prominent voice in interventional psychiatry, measurement-based care, and youth mental health. Host of the Frontier Psychiatrists.
Pr. Fabien Vinckier, MD, PhD
Professor of Psychiatry · GHU Paris
PI of MOODELING (600-patient observational cohort) and COGPSY (NCT07295652). Co-lead of the Emobot × EMOKET integration at GHU Paris Psychiatrie & Neurosciences.
Pr. Chantal Henry, MD, PhD
Professor of Psychiatry · GHU Paris · Sorbonne Université
Mood-disorders and bipolar expert. PI of EMOKET (NCT06630065). Collaboration partner for Emobot's bipolar disorder cohort (EMC2-BD).
Pr. Ron Albucher, MD
Professor of Psychiatry, UCSF · President of IEDTA
President of the International Eating Disorder Treatment Association (IEDTA). US clinical advisor. Deep experience in TMS and depression treatment programs at academic centers.
Strategic advisors
Operators and researchers scaling Emobot.
Jérôme Monceaux
Entrepreneur · AI robotics
Co-founder of Aldebaran Robotics (NAO/Pepper) and Spoon.ai. Advisor on deep-tech scaling and consumer AI.
Fabrice Bonan
Entrepreneur · Data platforms
Serial entrepreneur and advisor on SaaS scaling and data infrastructure.
Dr. Alain Toledano, MD
Clinician · Oncologist
MD and healthcare entrepreneur. Advisor on clinical adoption and patient-centered design.
Hugo Thimonier
Research · AI & health
Academic advisor bridging AI research and clinical applications.
Academic partners
Validated across 7 institutions on 3 continents.
Paris · FR
Boston · USA
Baltimore · USA
San Diego · USA
Montréal · CA
New Haven · USA
Berlin · DE
Clinical & network partners
From flagship networks to single-site IP practices.
Flagship clinical partnership
Hope Therapeutics · NRx Pharmaceuticals (Nasdaq: NRXP)
Dr. Jonathan Javitt, MD, MPH · Founder & CEO
Deployed across their US IP clinic network. Announced March 30, 2026.
National IP clinic network
Radial Health
Dr. Carlene MacMillan, MD (CPO) · Dr. Owen Muir, MD (CMO)
National interventional-psychiatry network (NY · CA · TN · SC · MO · CT). $50M Series A led by General Catalyst, 2025.
NYC IP practice
Thrive Mind Psychiatry
Dr. Marcel Green, MD · Founder & Medical Director
Holistic interventional-psychiatry practice offering TMS, ketamine and stellate ganglion block.
Great Neck, NY
Great Neck Psychiatry
Dr. Adarsh K. Gupta, MD · Medical Director (Harvard-trained, 4 board certifications)
Sleep, TMS & wellness psychiatry practice. Early US deployment.
Company timeline
Founded April 2022. Straight into psychiatry.
April 2022
Emobot founded in Paris, HQ at the Paris Brain Institute (ICM).
2022
First scientific collaborations with GHU Paris (Pr Vinckier) around multimodal passive monitoring in mood disorders.
2023
MOODELING launched (ID-RCB 2023-A02264-41, GHU Paris, 600 patients). First patents filed on passive multimodal depression monitoring.
2024
EMC1 clinical validation study launches in France (NCT06601140, Pr Schwan, CHU Nantes/Rennes). First US academic collaborations.
2025
Portfolio expands to 10+ studies across France, USA, Canada and Germany. Must-D (UCSD/FHCSD, ~800 patients) goes live. EMC2FR and EMC2-BD clinical validation studies advance the CE Mark pathway.
January 2026
US FDA clearance study scoped (EMC1-MDD-US, N=92). French reimbursement RCT (REMOOD, N=504) scheduled.
March 2026
Strategic partnership with Hope Therapeutics (NRx Pharmaceuticals, Nasdaq: NRXP) announced: deployment across their US IP clinic network.
April 2026
Emobot × EMOKET × COGPSY integration announced at GHU Paris. emobothealth.com goes live.
Intellectual property
4 patents. Filed and granted.
Passive multimodal depression monitoring via smartphone sensors
On-device neural network for facial affect analysis without data transmission
Vocal biomarker extraction for continuous mood-state estimation
Multimodal fusion architecture for psychiatric severity scoring
Want to build with us?
We’re always interested in clinical research partnerships, academic collaborations, and conversations with interventional psychiatry clinics ready to close the monitoring gap.
General contact: contact@emobothealth.com